ZCM
ABEO icon

Zebra Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Zebra Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-607
Closed -$50K – 227
2019
Q4 		$50K Buy
+607
New +$42.8K 0.04% 282

Other funds holding ABEO

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Zebra Capital Management's ABEO Position: Q1 2020 in Review

Zebra Capital Management sold out of Abeona Therapeutics (ABEO) in Q1 2020, closing a stake of 607 shares — an estimated $50K sold.

Zebra Capital Management first reported a position in ABEO in Q4 2019 and held it in 1 quarter. The position peaked at $50K in Q4 2019. 80 funds tracked by Wall St. Rank hold ABEO as of Q1 2020.

  • Zebra Capital Management reported no remaining Abeona Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Zebra Capital Management sold 607 Abeona Therapeutics shares in Q1 2020, an estimated $50K.
  • Zebra Capital Management first reported a position in Abeona Therapeutics in Q4 2019 and held it in 1 quarter.
  • Zebra Capital Management's Abeona Therapeutics position peaked at $50K in Q4 2019.
  • 80 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2020.

Based on Zebra Capital Management's 13F filing for Q1 2020, filed 15 May 2020.